Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tobira Therapeutics

Tobira Therapeutics
2006 FOUNDED
M&A STATUS
11-20 EMPLOYEES
M&A LATEST DEAL TYPE
$1.7B LATEST DEAL AMOUNT
Description

Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Primary Office
  • 701 Gateway Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tobira Therapeutics’s full profile, request a free trial.

Tobira Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 03-Oct-2016 $1.7B 000.00 00.00 Completed Generating Revenue
7. Reverse Merger 05-May-2015 000.00 Completed Clinical Trials - Phase 3
6. IPO 05-May-2015 0000 00000 Cancelled Clinical Trials - Phase 3
5. Convertible Debt 09-Mar-2015 0000 000.00 Completed Clinical Trials - Phase 3
4. Debt - General 30-Jun-2014 0000 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 30-Jul-2012 0000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 29-Sep-2010 $21.2M $52.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-2007 $31M $31M 000.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Tobira Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Tobira Therapeutics Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Metacrine Venture Capital-Backed San Diego, CA 00 00000 000000000 00000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 00000000000 00000
0000 000000000000 Venture Capital-Backed Cambridge, MA 00 0000 000000000000 0000
000000 00000000000 Venture Capital-Backed New York, NY 000.00 00000000000 000.00
000000 Venture Capital-Backed Austin, TX 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Tobira Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 05-May-2015 000000000000000000 Biotechnology
To view this company’s complete investment and acquisition history, request access »

Tobira Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Tobira Therapeutics Executive Team (11)

Name Title Board
Seat
Contact
Info
Martine Kraus Ph.D Vice President, Regulatory Affairs
Mark Menning Ph.D Director of Pharmaceutical Sciences
Laurent Fischer MD Board Member & Chief Executive Officer
Eric Lefebvre MD Chief Medical Officer

7 Former Executives

You’re viewing 4 of 11 executives. Get the full list »

Tobira Therapeutics Board Members (11)

Name Representing Role Since Contact
Info
Carol Brosgart MD Self Board Member 000 0000
Graeme Moyle MD Self Board Member 000 0000
Gwen Melincoff Self Board Member 000 0000
Jeffrey Cooper Self Board Member 000 0000
Laurent Fischer MD Tobira Therapeutics Board Member & Chief Executive Officer 000 0000

6 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »